Welcome to our dedicated page for Anixa Biosciences news (Ticker: $ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anixa Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anixa Biosciences's position in the market.
Anixa Biosciences, a clinical-stage biotechnology company, announced an expanded partnership with Cleveland Clinic to develop novel cancer vaccines targeting various cancer types. The vaccines focus on a unique scientific approach by immunizing against 'retired' proteins found in cancer cells, aiming to destroy cancer cells as they arise and prevent tumor formation. Collaborating on breast cancer and ovarian cancer vaccines, the partnership aims to lead in cancer research with promising preliminary data.
Anixa Biosciences, Inc. CEO Dr. Amit Kumar was featured on the 'Target: Cancer Podcast' by oncologist Dr. Sanjay Juneja, discussing 'The Vaccine That Could End Breast Cancer.' The podcast highlighted Anixa's unique vaccine technology aiming to prevent the growth and spread of cancer cells. Dr. Juneja praised the potential impact of Anixa's vaccines on cancer treatment.
Anixa Biosciences, a clinical-stage biotechnology company, will participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024. The CEO will present the company's cancer treatment and prevention programs, including a breast cancer vaccine in Phase 1 trials and a CAR-T cell therapy for ovarian cancer in Phase 1 trials. The company has a capital efficient business model with strong positive data and no debt.
